Alapis enters MoU with China's CSPC Pharma on areas of collaboration

Greek drugmaker Alapis SA (APSHF: PK) has signed a memorandum of understanding (MoU) with one of China's leading pharmaceutical companies, CSPC Pharmaceutical Group, to explore avenues of collaboration in the fields of:

•  sourcing of raw materials, such as APIs, for the production of Alapis' own pharmaceuticals products;

•  utilizing Alapis’ R&D expertise and infrastructure to co-develop new product formulations as well as to register and commercialize existing CSPC products into Greece and other markets where the company is present;